Nutritional supplements that contain curcumin -- a natural anti-inflammatory compound -- may protect the eyes from the ...

The therapy, called photobiomodulation or “red light” therapy, can reduce the risk of vision loss and slow progression of the ...

Preliminary data from a late stage clinical trial of a retinal implant showed promising results, Science Corporation said ...

A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...

There are various factors that may potentially increase the risk of developing AMD, such as advancing age (over 50); having a ...

The study was designed to demonstrate PRIMA’s safety and efficacy to reach European market approval (CE mark). PRIMA, owned ...

Alkeus Pharmaceuticals’ study results from Gildeuretinol shows significant trend in slowing geographic atrophy: Cambridge, Massachusetts Friday, October 25, 2024, 10:00 Hrs [IST ...

The following is a summary of “Submacular hemorrhage rates following anti-vascular endothelial growth factor injections for ...

An investigational antibody demonstrated an ability to preserve vision in people with geographic atrophy from dry age-related ...

Investment analysts at StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a report released on Friday. The brokerage set a “sell” rating on the ...

Pharmaceuticals announced that the first patient has been dosed in the Phase 3 LUGANO clinical trial of DURAVYU, formerly ...